Scarica l'app Stockscreener
1.07
6.14%
-0.07
Dopo l'orario di chiusura:
1.10
0.03
+2.80%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ONCT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.14
Aprire:
$1.13
Volume 24 ore:
21,313
Relative Volume:
0.23
Capitalizzazione di mercato:
$3.20M
Reddito:
-
Utile/perdita netta:
$-39.48M
Rapporto P/E:
-1.4079
EPS:
-0.76
Flusso di cassa netto:
$-32.16M
1 W Prestazione:
-17.05%
1M Prestazione:
-25.44%
6M Prestazione:
-87.64%
1 anno Prestazione:
-82.75%
Intervallo 1D:
$1.07
$1.13
Intervallo di 1 settimana:
$1.03
$1.30
Portata 52W:
$1.03
$13.14
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
Nome
Oncternal Therapeutics Inc
Settore
Industria
Telefono
(858) 434-1113
Indirizzo
12230 EL CAMINO REAL, SAN DIEGO, CA
Confronta ONCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ONCT | 1.07 | 3.20M | 0 | -39.48M | -32.16M | -0.76 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-07 | Iniziato | Oppenheimer | Outperform |
| 2021-02-23 | Iniziato | Northland Capital | Outperform |
Oncternal Therapeutics Inc Borsa (ONCT) Ultime notizie
Oncternal announces workforce reduction, executive changes - Investing.com
Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks
ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Marketscreener.com
Oncternal reports positive prostate cancer treatment results By Investing.com - Investing.com Australia
Oncternal reports positive prostate cancer treatment results - Investing.com India
Oncternal Therapeutics Announces Updated Safety and - GlobeNewswire
B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - Defense World
ONCT Stock Touches 52-Week Low at $1.19 Amid Market Challenges - Investing.com Australia
Oncternal Therapeutics Inc (ONCT) Q2 2024 Earnings Call Highlights: Advancements in Clinical ... - Yahoo Finance Australia
Oncternal stock jumps 9% on FDA fast track designation - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.58% - MSN
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges - Investing.com Australia
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Oncternal Therapeutics (ONCT) - Defense World
Omnicell Appoints Nnamdi Njoku as New COO - TipRanks
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
ONON’s Stock Market Adventure: 85.15% YTD Growth Amidst Volatility - The InvestChronicle
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer - Silicon UK
ONMD’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Levi & Korsinsky Notifies Shareholders of Outset Medical, - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire
Fred Alger Management LLC Has $44.73 Million Position in On Holding AG (NYSE:ONON) - MarketBeat
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily
On Holding's Options Frenzy: What You Need to Know - Benzinga
This Option Provides Gains By Coasting With On Running Shoes - Investor's Business Daily
ONON’s valuation metrics: A comprehensive analysis - US Post News
OM Stock on the Rise: A Promising Investment - The InvestChronicle
Was Outset Medical Inc (OM)’s session last reading good? - US Post News
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Views of Wall Street’s Leading Experts on Onconetix Inc - SETE News
Financial Metrics Unveiled: Outset Medical Inc (OM)’s Key Ratios in the Spotlight - The Dwinnex
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Outset Medical (OM) Shares Down 94% Since Disclosing FDA - GlobeNewswire
On Holding Options Trading: A Deep Dive into Market Sentiment - Benzinga
ON (NYSE:ONON) Rating Increased to Neutral at Bank of America - MarketBeat
OM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Outset Medical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Onsemi Could Be Set Up For a Solid Rebound: Here's Why - MarketBeat
Kayne Anderson Rudnick Investment Management LLC Boosts Stock Position in On Holding AG (NYSE:ONON) - MarketBeat
Onconetix (NASDAQ:ONCO) Shares to Reverse Split on Tuesday, September 24th - Defense World
Bradley Foster & Sargent Inc. CT Increases Stock Position in On Holding AG (NYSE:ONON) - Defense World
Onsemi (NASDAQ:ON) Holdings Raised by Argent Trust Co - Defense World
Why Onconetix (ONCO) Shares Are Down 27% - Benzinga
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - GlobeNewswire
On Holding AG (NYSE:ONON) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Oncolytics Biotech reports positive results from breast cancer study | 2024-09-19 | Investing News - Stockhouse Publishing
Oncternal Therapeutics Inc Azioni (ONCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):